Literature DB >> 23332934

Prognostic contributions of the underlying inflammatory disease and acute organ dysfunction in critically ill patients with systemic rheumatic diseases.

Stanislas Faguer1, Magali Ciroldi, Eric Mariotte, Lionel Galicier, Michel Rybojad, Emmanuel Canet, Djaouida Bengoufa, Benoit Schlemmer, Elie Azoulay.   

Abstract

BACKGROUND: Knowledge about the clinical features, outcomes and predictors of short-term mortality in critically ill patients with systemic rheumatic disease (SRD) requires further characterization.
METHODS: Single center retrospective observational cohort study of 149 critically ill patients with SRD followed in a French medical intensive care unit over a 20-year period. Multivariate logistic regression was used to identify predictors of day-30 mortality.
RESULTS: Most patients (63%) had systemic lupus erythematosus, rheumatoid arthritis, or systemic sclerosis. The critical illness usually developed late after the diagnosis of SRD (median time to ICU admission 82 months, IQR [9-175] in the 127 patients with a previous diagnosis of SRD). Two-thirds of patients were taking immunosuppressive drugs to treat their SRD. Reasons for ICU admission were infection (47%), SRD exacerbation (48%), and iatrogenic complications (11%); the most common organ failure was acute renal failure. Thirty-day mortality was 16%. Predictors of 30-day mortality were the LODS score on day 1 (OR 1.3 (1.06-1.48)), bacterial pneumonia (OR 3.8 (1.03-14.25)), need for vasoactive drugs (OR 7.1 (1.83-27.68)), SRD exacerbation (OR 4.3 (1.15-16.53)), and dermatomyositis (OR 9.2 (1.05-80.78)) as the underlying disease. Year of ICU admission was not significantly associated with 30-day survival.
CONCLUSION: Patients with SRD are mostly admitted in the ICU with infection or SRD exacerbation, and can be treated with immunosuppressive therapy and life-sustaining interventions with acceptable 30-day mortality. Death is associated with both the severity of the acute medical condition and the characteristics of the underlying SRD.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23332934     DOI: 10.1016/j.ejim.2012.11.018

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  15 in total

1.  Highlighting the important effect of systemic lupus erythematosus on platelet count of critically ill patients.

Authors:  Otavio T Ranzani; Fernando G Zampieri; Marcelo Park
Journal:  Intensive Care Med       Date:  2013-07-17       Impact factor: 17.440

2.  In-ICU-acquired infections in flare-up systemic rheumatic disease patients receiving immunosuppressant.

Authors:  Florence Assan; Pierre Bay; Alexis Mathian; Guillaume Hekimian; Nicolas Bréchot; Paul Quentric; Quentin Moyon; Matthieu Schmidt; Fleur Cohen-Aubart; Julien Haroche; Zahir Amoura; Charles-Edouard Luyt; Alain Combes; Marc Pineton de Chambrun
Journal:  Clin Rheumatol       Date:  2022-05-10       Impact factor: 3.650

Review 3.  Patients with systemic rheumatic diseases admitted to the intensive care unit: what the rheumatologist needs to know.

Authors:  Mohanned Mustafa; Easwaradhas Gladston Chelliah; Michael Hughes
Journal:  Rheumatol Int       Date:  2018-03-16       Impact factor: 2.631

4.  [Outcome of intensive medical care for inflammatory rheumatic diseases].

Authors:  L A Rütter; S Rütter; M Winkler; G Keyßer
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

5.  Non-invasive ventilation in immunocompromised patients with acute hypoxemic respiratory failure.

Authors:  Lorenzo Del Sorbo; Angela Jerath; Martin Dres; Matteo Parotto
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

Review 6.  Antiphospholipid antibodies in critically ill patients.

Authors:  Juliana Vassalo; Nelson Spector; Ernesto de Meis; Márcio Soares; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2014 Apr-Jun

7.  Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis.

Authors:  Santiago Bernal-Macías; Benjamín Reyes-Beltrán; Nicolás Molano-González; Daniel Augusto Vega; Claudia Bichernall; Luis Aurelio Díaz; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Lupus Sci Med       Date:  2015-12-01

8.  High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial.

Authors:  Elie Azoulay; Virginie Lemiale; Djamel Mokart; Saad Nseir; Laurent Argaud; Frédéric Pène; Loay Kontar; Fabrice Bruneel; Kada Klouche; François Barbier; Jean Reignier; Anabelle Stoclin; Guillaume Louis; Jean-Michel Constantin; Julien Mayaux; Florent Wallet; Achille Kouatchet; Vincent Peigne; Pierre Perez; Christophe Girault; Samir Jaber; Johanna Oziel; Martine Nyunga; Nicolas Terzi; Lila Bouadma; Christine Lebert; Alexandre Lautrette; Naike Bigé; Jean-Herlé Raphalen; Laurent Papazian; Antoine Rabbat; Michael Darmon; Sylvie Chevret; Alexandre Demoule
Journal:  Trials       Date:  2018-03-05       Impact factor: 2.279

9.  Mortality of Sepsis in Patients With Rheumatoid Arthritis: A Single-Center Retrospective Analysis and Comparison With a Control Group.

Authors:  Marco Krasselt; Christoph Baerwald; Sirak Petros; Olga Seifert
Journal:  J Intensive Care Med       Date:  2020-04-06       Impact factor: 3.510

10.  Dermatomyositis and Polymyositis in the Intensive Care Unit: A Single-Center Retrospective Cohort Study of 102 Patients.

Authors:  Jin-Min Peng; Bin Du; Qian Wang; Li Weng; Xiao-Yun Hu; Chan-Yuan Wu; Yan Shi
Journal:  PLoS One       Date:  2016-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.